GlassScriptPhysician profile
Caitlin Estep
NPI 1386251635
$2,167.75
in general payments reported to CMS, 2019-2025
24 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $445 · 2023: $281 · 2024: $617 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,004.07 | 2021-2025 | |
| Boston Scientific Corporation | $165.76 | 2024 | Watchman Access System |
| Ge Healthcare | $111.99 | 2025 | |
| Alexion Pharmaceuticals, INC. | $99.80 | 2022-2024 | Ultomiris |
| Lilly USA, LLC | $95.31 | 2022-2025 | Emgality, Reyvow, Kisunla |
| Pfizer INC. | $78.20 | 2023-2025 | |
| Eisai INC. | $70.67 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.22 | 2024-2025 | Hyqvia |
| Sk Life Science, INC. | $61.62 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $50.46 | 2023-2025 | Ongentys, Ingrezza |
| Otsuka America Pharmaceutical, INC. | $43.97 | 2024 | Rexulti |
| Csl Behring | $39.20 | 2024-2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $38.96 | 2024 | Austedo Xr |
| Tanabe Pharma America, INC. | $34.99 | 2024 | |
| Stryker Corporation | $28.10 | 2024 | Trevo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $25.64 | 2022 | |
| Grifols USA, LLC | $23.47 | 2025 | Gamunex-C |
| Janssen Biotech, INC. | $21.04 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $19.98 | 2021 | |
| Amneal Pharmaceuticals LLC | $19.45 | 2024 | Rytary |
| Amgen INC. | $18.44 | 2021 | |
| Ucb, INC. | $17.89 | 2024 | Zilbrysq |
| Neurelis, INC. | $17.82 | 2024 | Valtoco |
| Acadia Pharmaceuticals INC | $17.70 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Estep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.